Drug profile · INN
tafasitamab-cxix
MONJUVI
tafasitamab-cxix (MONJUVI) is a b-lymphocyte antigen cd19 binding agent. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — tafasitamab-cxix
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
tafasitamab-cxix (MONJUVI) is a b-lymphocyte antigen cd19 binding agent. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
B-lymphocyte antigen CD19 binding agent
Primary target: B-lymphocyte antigen CD19
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Related & competitor drugs
Frequently asked questions
What is tafasitamab-cxix?
tafasitamab-cxix (MONJUVI) is a b-lymphocyte antigen cd19 binding agent. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for tafasitamab-cxix?
MONJUVI is a marketed brand name for tafasitamab-cxix. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tafasitamab-cxix?
tafasitamab-cxix has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.